Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
2017-001805-34Phase 2
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in acute lymphoblastic leukemia (ALL), sponsored by Novartis. Primary endpoint: Hematologic response.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2017-001805-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001805-34.